Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b conjugate vaccine PRP-OMPC
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae type b conjugate vaccine PRP-OMPC is an inactivated bacterial vaccine that contains the capsular polysaccharide (polyribosylribitol phosphate, PRP) of Haemophilus influenzae type b conjugated to an outer membrane protein complex (OMPC) derived from Neisseria meningitidis. Conjugation to OMPC enhances immunogenicity, especially in infants and young children. The vaccine is used for the prevention of invasive diseases caused by Haemophilus influenzae type b, such as meningitis, pneumonia, and epiglottitis. It primes the immune system to recognize and clear H. influenzae type b by inducing anti-PRP polysaccharide antibodies through T-cell dependent immune mechanisms, thereby providing long-term protection. Primary indication is immunization of infants and young children.
- Brand names
- HibTITER
- Other names
- Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)Hib PRP-OMPCHaemophilus influenzae type b vaccine (meningococcal conjugate)
02
Targets
TLR2 (Toll-like Receptor 2)PRNP (Cellular Prion Protein)Neisseria meningitidis serogroup B outer membrane antigens
Beyond the preview
Go deeper on haemophilus influenzae type b conjugate vaccine PRP-OMPC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b conjugate vaccine PRP-OMPC.